BENDAMUSTINE

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Length of Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bendeka</td>
<td>bendamustine</td>
<td>Per Medical Guidelines</td>
</tr>
<tr>
<td>Treanda</td>
<td>bendamustine</td>
<td>Per Medical Guidelines</td>
</tr>
</tbody>
</table>

Approvable Criteria:

- Bendeka/Treanda is prescribed by, or in consultation with, an oncologist; **AND**
- Member is 18 years of age or older; **AND**
- Member has a diagnosis of chronic lymphocytic leukemia (CLL); **OR**
- Member has a diagnosis of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen

Dosage and Administration:

- **CLL:** 100mg/m² on days 1 and 2 of a 28-day treatment cycle (for up to 6 cycles)
- **NHL:** 120mg/m² on days 1 and 2 of a 21-day treatment cycle (for up to 8 cycles)

Approvable Duration:

- **CLL:** 6 months
- **NHL:** 8 months

*For Baptist Health Plan to recognize a chemotherapy regimen as an accepted approach to treatment it must be included in the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®).*

*References:*